Document Type : Original Article(s)
Authors
- Ehsan Shahverdi 1
- Pedram Karami 2
- Farzaneh Tavakoli 3
- Massoumeh Maki 4
- Meysam Moazzami 5
- Fatemeh Feizi 6
- Peyman Salamati 7
- Alireza Lotfipour 7
- Mohammad Ali Ehsani 7
1 Department of Cardiology, Angiology and Sleep Medicine, Bonifatius Hospital Lingen, Lingen, Germany
2 Department of Otorhinolaryngology-Head and Neck Surgery, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
3 Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Nursing and Midwifery, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
5 Department of Pediatrics, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran
6 Department of Laboratory Hematology and Blood Bank, School of Allied Medical Sciences, Shahid Beheshi University of Medical Science, Tehran, Iran
7 Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of lymphoid neoplasms resulting from the proliferation of malignant lymphoid cells. The aim of this study was to evaluate treatment-related complications in children with ALL receiving the Medical Research Council (MRC) UKALL X protocol.
Methods: In this retrospective cross-sectional study, children with ALL receiving the MRC UKALL X protocol from 2008 to 2015 in Bahrami University Hospital, Iran, were enrolled. The clinical and morphological features were analysed and treatment-related complications were assessed.
Results: Out of 67 children with ALL receiving the MRC UKALL X protocol, 44 (65.6 %) were boys and 23 (34.4%) were girls. Seven patients (10.7%) relapsed in the three years of diagnosis, and 50 children (74.6%) had an overall survival of three years. Average age in three-year-survival group and mortality group was 6.92 (SD: 3.96) and 6.35 (SD: 7.47), respectively (P= 0.38).
Conclusion: Overall survival and relapse rates in this study confirm that this protocol is an appropriate treatment strategy.
Keywords
)